US20010019838A1 - Decaprenyl diphosphate synthetase gene - Google Patents
Decaprenyl diphosphate synthetase gene Download PDFInfo
- Publication number
- US20010019838A1 US20010019838A1 US09/803,951 US80395101A US2001019838A1 US 20010019838 A1 US20010019838 A1 US 20010019838A1 US 80395101 A US80395101 A US 80395101A US 2001019838 A1 US2001019838 A1 US 2001019838A1
- Authority
- US
- United States
- Prior art keywords
- seq
- synthetase
- gene
- acgt
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000364 Ligases Proteins 0.000 title claims abstract description 89
- FSCYHDCTHRVSKN-DJNGBRKISA-N (2Z,6Z,10Z,14Z,18Z,22Z,26Z,30Z,34E)-decaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O FSCYHDCTHRVSKN-DJNGBRKISA-N 0.000 title description 3
- 102000003960 Ligases Human genes 0.000 claims abstract description 81
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 239000013598 vector Substances 0.000 claims abstract description 43
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 31
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 238000012217 deletion Methods 0.000 claims abstract description 10
- 230000037430 deletion Effects 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 6
- 238000007792 addition Methods 0.000 claims abstract description 6
- 238000006467 substitution reaction Methods 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 description 72
- 239000003795 chemical substances by application Substances 0.000 description 48
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 42
- 239000012634 fragment Substances 0.000 description 33
- 102000004190 Enzymes Human genes 0.000 description 32
- 108090000790 Enzymes Proteins 0.000 description 32
- 229940088598 enzyme Drugs 0.000 description 32
- 241000588724 Escherichia coli Species 0.000 description 31
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 30
- 241000589597 Paracoccus denitrificans Species 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 239000002585 base Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 235000017471 coenzyme Q10 Nutrition 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 14
- 102000019337 Prenyltransferases Human genes 0.000 description 12
- 108050006837 Prenyltransferases Proteins 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 12
- 229940035936 ubiquinone Drugs 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000001177 diphosphate Substances 0.000 description 10
- 235000011180 diphosphates Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002105 Southern blotting Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- -1 more than 23 Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000013404 Geranyltranstransferase Human genes 0.000 description 7
- 108010026318 Geranyltranstransferase Proteins 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- IVLBHBFTRNVIAP-MEGGAXOGSA-N all-trans-nonaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O IVLBHBFTRNVIAP-MEGGAXOGSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920001550 polyprenyl Polymers 0.000 description 5
- 125000001185 polyprenyl group Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 150000003505 terpenes Chemical class 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 4
- 102000013563 Acid Phosphatase Human genes 0.000 description 4
- 108010051457 Acid Phosphatase Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 101000897764 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Hexaprenyl pyrophosphate synthase Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 125000001655 ubiquinone group Chemical group 0.000 description 4
- ICFIZJQGJAJRSU-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-<3,7,11,15,19,23,27,31-octamethyl-dotriacontaoctaen-(2,6,10,14,18,22,26,30)-yl>benzochinon Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ICFIZJQGJAJRSU-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 3
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LSJLEXWXRKTZAJ-YUIIPXGZSA-N all-trans-heptaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O LSJLEXWXRKTZAJ-YUIIPXGZSA-N 0.000 description 3
- NGFSMHKFTZROKJ-MMSZMYIBSA-N all-trans-hexaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O NGFSMHKFTZROKJ-MMSZMYIBSA-N 0.000 description 3
- IKKLDISSULFFQO-DJMILUHSSA-N all-trans-octaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O IKKLDISSULFFQO-DJMILUHSSA-N 0.000 description 3
- 125000000746 allylic group Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 244000000000 soil microbiome Species 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- ICFIZJQGJAJRSU-SGHXUWJISA-N ubiquinone-8 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ICFIZJQGJAJRSU-SGHXUWJISA-N 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000588696 Pantoea ananatis Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003669 ubiquinones Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- PJERCKGJJBCWEC-UHFFFAOYSA-N 2-prenyl-1,4-benzoquinone Chemical compound CC(C)=CCC1=CC(=O)C=CC1=O PJERCKGJJBCWEC-UHFFFAOYSA-N 0.000 description 1
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 1
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100024482 Cell division cycle-associated protein 4 Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 1
- BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 description 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- DMHGKBGOUAJRHU-RVMXOQNASA-N Ile-Arg-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N DMHGKBGOUAJRHU-RVMXOQNASA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 description 1
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- 101001045418 Micrococcus luteus Hexaprenyl-diphosphate synthase large subunit ((2E,6E)-farnesyl-diphosphate specific) Proteins 0.000 description 1
- 101001045441 Micrococcus luteus Hexaprenyl-diphosphate synthase small subunit ((2E,6E)-farnesyl-diphosphate specific) Proteins 0.000 description 1
- 244000128833 Mimulus luteus Species 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- KAGCQPSEVAETCA-JYJNAYRXSA-N Phe-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N KAGCQPSEVAETCA-JYJNAYRXSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- 108010065064 acetaldehyde dehydrogenase (acylating) Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- NTXGVHCCXVHYCL-RDQGWRCRSA-N all-trans-undecaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O NTXGVHCCXVHYCL-RDQGWRCRSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 101150002273 dpo3 gene Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- OINNEUNVOZHBOX-KGODAQDXSA-N geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C\CC\C(C)=C\CO[P@@](O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-KGODAQDXSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108091022928 glucosylglycerol-phosphate synthase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000012643 polycondensation polymerization Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 1
- 108091005629 prenylated proteins Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
Definitions
- the present invention relates to a decaprenyl diphosphate synthetase, a gene coding for the synthetase, a recombinant vector comprising the gene, a transformant transformed with the vector, a method for producing a decaprenyl diphosphate synthetase, and a method for producing ubiquinone-10.
- Isoprenoids are the most varied group of compounds including more than 23,000 species occurring in nature. They include sterols, carotenoids, sugar carrier lipids, prenyl quinones, prenylated proteins, etc. (FIG. 1). Those enzymes which catalyze the formation of carbon skeletons that will be the basis for the biosynthesis of these isoprenoid compounds (i.e., enzymes which catalyze the head-to-tail type condensation polymerization of isopentenyl diphosphate (IPP) that is 5-carbon isoprene unit) are generically called as prenyl diphosphate synthetase.
- IPP isopentenyl diphosphate
- Prenyl diphosphate synthetase is classified into 4 groups depeding on the chain length, conformation, etc. of the prenyl diphosphate generated (Table 1). TABLE 1 Classification of Prenyltransferase Major Group Structure Characteristic Products Short-chain prenyl Homodimer Soluble C 15 , C 20 diphosphate synthetase Medium-chain prenyl Heterodimer Soluble C 30 , C 35 diphosphate synthetase (E)-polyprenyl Homodimer Activated by C 40 , C 45 , C 50 diphosphate synthetase carrier proteins. (E)-polyprenyl Homodimer Activated by C 45 , C 55 diphosphate synthetase lipids.
- Short-chain prenyl diphosphate synthetase includes geranyl diphosphate (GPP, C10) synthetase, farnesyl diphosphate (FPP, C15) synthetase (Eberhardt, N. L. et al., (1975) J. Biol. Chem. 250:863-866), geranylgeranyl diphosphate (GGPP, C20) synthetase (Sagami, H. et al. (1994) J. Biol. Chem. 269: 20561-20566) and the like.
- the short-chain prenyl diphosphates biosynthesized by these enzymes are water-soluble. They may be supplied as an allyl primer substrate for polyprenyl diphosphate synthetase belonging to other groups.
- Medium-chain prenyl diphosphate synthetase includes hexaprenyl diphosphate (HexPP, C30) synthetase (Fujii, H. et al., (1982) J. Biol. Chem., 257:14610), heptaprenyl diphosphate (HepPP, C35) synthetase (Takahashi, I. et al., (1980) J. Biol Chem., 255: 4539) and the like.
- HexPP hexaprenyl diphosphate
- HepPP heptaprenyl diphosphate
- enzymes are greatly different from the short-chain prenyl diphosphate synthetase described above in that they are heterodimeric enzymes composed of two proteins each of which does not have a catalytic function alone. Usually, these two proteins are dissociated, but when a substrate is present, they associate with each other to manifest a function as an enzyme. Although those products produced by such enzymes are highly hydrophobic and apt to form micelles, they do not require lipids nor surfactants for the manifestation of their enzyme activity. This is considered due to the fact that the medium-chain prenyl diphosphate synthetase is a special system in which such dynamic dissociation and association are repeated.
- E-type long-chain prenyl diphosphate synthetase includes octaprenyl diphosphate (OctPP, C40) synthetase, decaprenyl diphosphate (DPP, C50) synthetase and the like.
- these enzymes are undissociable homodimers and activated by polyprenyl diphosphate carrier proteins (Ohnuma, S. et al., (1991) J. Biol. Chem. 266: 23706-23713). This activation is believed to maintain the catalyst turnover by removing hydrophobic reaction products from the active sites of these enzymes.
- Z-type long-chain prenyl diphosphate synthetase includes nonaprenyl diphosphate (E,E-farnesyl-all-Z-hexaprenyl diphosphate, C45) synthetase, undecaprenyl diphosphate (E,E-farnesyl-all-Z-octaprenyl diphosphate, C55) synthetase and the like.
- Reaction products generated by these enzymes work as sugar carrier lipids in the biosynthesis of bacterial cell walls.
- These enzymes need the addition of a phospholipid or surfactant for the manifestation of their activity.
- DPP synthetase which is classified into prenyltransferase III, is also known to require a surfactant for the manifestation of its enzyme activity.
- a soil bacterium Paracoccus denitrificans is a bacterium which is believed to be the origin of human mitochondria.
- the respiratory chain and the oxidative phosphorylation mechanism of this bacterium are more efficient and more united as one organization than those of other bacteria.
- the characteristics of P. denitrificans are more closer to those of mitochondria (John, P. et al., (1975) Nature, 254, 495-498).
- Three types of prenyl diphosphate synthetase activities have been confirmed from P. denitrificans (FIG. 2).
- FPP synthetase which catalyzes E-type condensation of dimethylallyl diphosphate (DMAPP) with 2 molecules of IPP to produce FPP
- NPP nonaprenyl diphosphate
- DPP synthetase which catalyzes E-type condensation of FPP with 7 molecules of IPP to produce DPP
- NPP produced by NPP synthetase becomes a sugar carrier lipid which is essential for the biosynthesis of the cell wall of this bacterium.
- prenyl diphosphate synthetases such as NPP synthetase and undecaprenyl diphosphate synthetase which catalyze Z-type condensation reaction have not been elucidated yet in relationships between their structures and enzymatic functions.
- DPP produced by DPP synthetase is metabolized on the prenyl side chain of ubiquinone-10 (a constituent of the electron transport system) produced by this bacterium.
- All of the C30-C50 polyprenyl diphosphates biosynthesized by bacterial prenyltransferase II or III are provided as a side chain precursor of the corresponding menaquinone or ubiquinone. Therefore, the chain length of the product of each enzyme is directly reflected in the side chain length of the prenylquinone of the bacterium from which the enzyme is derived.
- ubiquinone-10 is industrially extracted from Paracoccus denitrificans and used as pharmaceuticals since it has the same side chain length as that of human coenzyme Q (CoQ).
- Ubiquinone has been known to be effective for chronic heart diseases (Yamamura, T. (1977) Clinical Status of Coenzyme Q and Prospects 281-298).
- Ubiquinone-10 is also effective as an antiarrhythmic agent and, thus, is utilized for the prevention of arrhythmia and the like (Fujioka, T. et al. (1983) Tohoku J. Exp. Med. 141, 453-463).
- the present invention relates to a recombinant protein (a) or (b) described below:
- the present invention also relates to a gene coding for the recombinant protein (a) or (b) described above.
- Specific examples of this gene include a gene comprising the base sequence shown in SEQ ID NO: 1.
- the present invention relates to a recombinant vector comprising the above gene.
- the present invention further relates to a transformant transformed with the above vector.
- the present invention further relates to a method for producing a decaprenyl diphosphate synthetase comprising culturing the above transformant in a medium and recovering a decaprenyl diphosphate synthetase from the resultant culture.
- the present invention further relates to a method for producing ubiquinone-10 comprising extracting ubiquinone-10 from the above transformant.
- FIG. 1 is a diagram showing the biosynthesis of isoprenoid compounds.
- FIG. 2 is a diagram showing the biosynthetic pathway of prenyl diphosphates in P. denitrificans.
- FIG. 3 is a diagram showing the design of PCR primers.
- FIG. 4 is a photograph showing the results of PCR.
- FIG. 5 is a diagram showing comparison of amino acid homology.
- FIG. 6 is a diagram showing the design of PCR primers.
- FIG. 7 provides two electrophorograms showing the results of Southern hybridization.
- FIG. 8 is an electrophorogram showing the results of Southern hybridization.
- FIG. 9 is an electrophorogram showing the results of Southern hybridization.
- FIG. 10 is a diagram showing the structure of plasmid p11A1.
- FIG. 11 is a diagram showing the open reading frame contained in plasmid p11A1.
- FIG. 12 is a diagram showing comparison of amino acid sequences for various prenyltransferases.
- FIG. 13 is an illustrative diagram showing genes located upstream and downstream of the gene of the present invention.
- FIG. 14 provides photographs of reversed phase thin layer liquid chromatograms.
- FIG. 15 is a photograph showing the results of SDS-polyacrylamide gel electrophoresis.
- FIG. 16 provides HPLC charts showing the results of analysis of quinone side chains.
- FIG. 17 is a graph showing the ratios of ubiquinone production in individual microorganisms.
- prenyl diphosphate synthetases (hereinafter, sometimes referred to as “prenyltransferase(s)”) have 7 regions which have been preserved highly beyond species (Koyama, T. et al., (1993) J. Biochem. 113:355).
- degenerate oligonucleotides for use as primers are designed based on the amino acid sequences highly preserved among various prenyltransferases.
- the gene of the present invention can be obtained by screening the genomic DNA using one of the amplified partial sequences as a probe.
- genomic DNA is prepared from cultures cells of a prenyl diphosphate synthetase producing bacterium such as the soil bacterium P. denitrificans.
- genomic DNA may be prepared easily by the following procedures.
- the above bacterium is inoculated into a medium containing 2 g of yeast extract, 10 g of Polypeptone, 1 g of MgSO 4 .7H 2 O and 1 liter of distilled water (802 medium) and cultured at 30° C. for one to several days (until saturation); subsequently, bacterial cells are treated with lysozyme and further treated with a surfactant such as sodium lauryl sulfate; thereafter, proteins are removed therefrom with an organic solvent such as phenol, chloroform or ether; then, genomic DNA is precipitated with ethanol.
- genomic DNA library is prepared by ligating the resultant genomic DNA to a vector plasmid.
- This preparation may be performed by conventional methods. For example, genomic DNA strand and plasmid DNA strand are cut with an appropriate restriction enzyme (e.g., EcoRI, BamHI, Hind III, Sau3AI, MboI, PstI); then, these strands are just treated with a DNA ligase (e.g., T4 DNA ligase), or they are treated with a DNA ligase after treatment with a terminal transferase or DNA polymerase depending on the states of the resultant fragment ends, to thereby ligate DNA strands (Molecular Cloning, Cold Spring Harbor Laboratory, 269, 1982; Methods in Enzymol., 68, 41, 1979).
- an appropriate restriction enzyme e.g., EcoRI, BamHI, Hind III, Sau3AI, MboI, PstI
- a DNA ligase e.g., T4 DNA ligas
- ⁇ phage vectors e.g., ⁇ gt10, Charon 4A, EMBL-3
- plasmid vectors e.g., pBR322, pSC101, pUC19, pUC119, pACYC117
- Escherichia coli e.g., DH1, HB101, JM109, C600, MV1184, TH2
- DH1, HB101, JM109, C600, MV1184, TH2 is transformed with the vector to obtain a genomic DNA library.
- probes to be used for screening the above genomic DNA library by hybridization are prepared.
- probes which are highly specific to a DNA of interest it is considered appropriate to prepare oligonucleotides coding for the regions with highly preserved amino acid residues among various organism species. These probes can be obtained by conventional chemical synthesis.
- amino acid sequences which satisfy the above conditions the following preserved amino acid sequences are selected based on FIG. 3.
- Regions I, II, III, IV, V and VI correspond to amino acid positions from 43 to 53, from 74 to 95, from 110 to 119, from 145 to 150, from 170 to 175 and from 204 to 230, respectively, of the amino acid sequence for a Bacillus stearothermophylus -derived heptaprenyl diphosphate synthetase disclosed in Koike T. et al., (1995) J. Biol. Chem. 270:18398-18400.
- Examination of preserved amino acid sequences in various organism species can be performed among known prenyl diphosphate synthetases, such as FPS synthetases from Bacillus stearothermophylus, Escherichia coli, Saccharomyces cerevisiae , rat and human; GGPS synthetases from Erwinia herbicola and Erwinia uredovora ; and HexPS synthetase from Saccharomyces cerevisiae.
- FPS synthetases from Bacillus stearothermophylus, Escherichia coli, Saccharomyces cerevisiae , rat and human
- GGPS synthetases from Erwinia herbicola and Erwinia uredovora
- HexPS synthetase from Saccharomyces cerevisiae.
- the following 12 degenerate primers are designed based on highly preserved amino acid sequences among various prenyltransferases and on those sequences which are peculiar to medium- or long-chain prenyltransferases such as hexaprenyl diphosphate (HexPP, C30) synthetase, heptaprenyl diphosphate (Hepp, C35) (Koike, T. et al. (1995) J. Biol. Chem. 270:18396-18400) synthetase and octaprenyl diphosphate (OctPP, C40) (Jeorg, J. et al., (1996) Proc. Natl. Acad. Sci. USA 91:2216-2220) synthetase.
- HexPP hexaprenyl diphosphate
- Hepp heptaprenyl diphosphate
- OctPP octaprenyl diphosphate
- S1 (designed based on SEQ ID NO: 3):
- S2 (designed based on SEQ ID NO: 4):
- A1 (designed based on SEQ ID NO: 13):
- A2 (designed based on SEQ ID NO: 8):
- A3 (designed based on SEQ ID NO: 9):
- A4 (designed based on SEQ ID NO: 10):
- A5 (designed based on SEQ ID NO: 11):
- A6 (designed based on SEQ ID NO: 12):
- the screening of P. denitrificans genomic DNA for the gene of the present invention can be performed by conventional methods such as Southern hybridization, colony hybridization, PCR or a combination of these methods.
- genomic DNA from P. denitrificans is subjected to PCR using a combination of the primers described above to thereby amplify a DNA fragment containing a part of a prenyl diphosphate synthetase gene.
- the fragment which is believed to contain a part of the target gene is separated by electrophoresis and recovered.
- E. coli is transformed with the vector, and the DNA fragment is cloned.
- the thus obtained DNA fragment (pCR14) is suitable as a probe for obtaining a full length prenyl diphosphate synthetase gene.
- probe pCR14 is a DNA fragment containing a part of the prenyl diphosphate synthetase gene of P. denitrificans .
- the screening for a gene encoding the peptide of the prenyl diphosphate synthetase of the invention is performed, for example, as described below using pCR14.
- genomic DNA partially digested with Sau3AI is electrophoresed. Resultant DNA fragments of 5-10 kbp are extracted from the agarose gel and inserted into the BamHI site of pUC119. With this plasmid, E. coli JM109 is transformed to prepare a DNA library. Then, colony hybridization is performed with pCR14 as a probe.
- Each of the clones thus obtained is digested with an appropriate restriction enzyme, followed by agarose gel electrophoresis. From the migration pattern and distance, a restriction map is prepared. Based on this map, deletion of the DNA fragment (i.e., to make the DNA fragment shorter) is carried out to thereby obtain a minimum clone exhibiting activity. Then, the base sequence for the activity-exhibiting DNA is analyzed.
- the base sequence may be determined using two plasmids which contain the same insert DNA truncated at one end in opposite directions.
- the screened clone is digested with an appropriate restriction enzyme (such as EcoRI, PstI) and cloned into a plasmid (such as pUC119, pUC19).
- an appropriate restriction enzyme such as EcoRI, PstI
- cloned into a plasmid such as pUC119, pUC19.
- the base sequence for the DNA of interest can be determined by conventional base sequence analysis methods, for example, the dideoxy method by Sangar et al. (Proc. Natl. Acad. Sci. USA (1977) 74:5463).
- the determination of the base sequence may be performed with an automatic base sequence analyzer such as T7 Sequencing Kit (Pharmacia).
- a region which is expected to be a prenyl diphosphate synthetase gene is integrated into an expression vector, with which E. coli is transformed.
- the transformant is cultured and resultant cells are crushed to obtain a crude enzyme extract.
- the prenyl diphosphate synthetase, particularly, decaprenyl diphosphate synthetase of the invention can be identified.
- the gene can be identified.
- the base sequence for the gene coding for the prenyltransferase of the invention is shown in SEQ ID NO: 1.
- the amino acid sequence for the prenyltransferase of the invention is shown in SEQ ID NO: 2.
- the amino acid sequence of SEQ ID NO: 2 may have a mutation such as deletion, substitution or addition of at least one amino acid (preferably, one or several amino acids) as long as it can exhibit prenyltransferase activity.
- a base sequence which codes for the same polypeptide and which is only different from SEQ ID NO: 1 in a degenerate codon(s) is also included in the gene of the present invention.
- the target gene can be obtained by hybridization with a DNA fragment prepared by chemical synthesis or PCR.
- a recombinant vector of the invention can be obtained by integrating the gene of the invention into an appropriate vector.
- a transformant of the invention can be obtained by introducing the recombinant vector into a host which is compatible with the initial vector.
- a purified gene is inserted into a restriction site or multi-cloning site of a suitable vector DNA to obtain a recombinant vector. With this vector, a host is transformed.
- a vector DNA into which a DNA fragment is inserted is not particularly limited as long as it is replicable in a host cell.
- a plasmid DNA or phage DNA may be used.
- plasmid pUC118 (Takara Shuzo)
- plasmid pUC119 (Takara Shuzo)
- pBluescript SK+ (Stratagene)
- pGEM-T Promega
- phage DNA M13mp18, M13mp19 or the like may be enumerated.
- any host may be used as long as it can express the gene of interest.
- Either an eukaryotic or prokaryotic cell may be used.
- bacteria such as Escherichia coli, Bacillus subtilis ; yeast such as Saccharomyces cerevisiae ; and animal cells such as COS cells, CHO cells, etc. may be enumerated.
- the recombinant vector of the invention is capable of autonomous replication in the host and yet has a constitution comprising a promoter, the gene of the invention and a transcription terminator sequence.
- E. coli include XL1-Blue (Stratagene) and JM109 (Takara Shuzo).
- Specific examples of an expression vector include pTrc99A and pET expression systems.
- any promoter may be used as long as it can express the gene of interest in the host such as E. coli .
- the promoter include E.
- E. coli - or phage-derived promoters such as trp promoter, lac promoter, PL promoter and PR promoter.
- the transformation of E. coli can be performed, for example, by the method of Hanahan (J. Mol. Biol. (1983) 166:557).
- an expression vector such as YEp13 or YCp50 may be used.
- a promoter such as gal 1 promoter or gal 10 promoter may be used, for example.
- electroporation Methods for introducing a recombinant vector into yeast
- the spheroplast method Proc. Natl. Acad. Sci. USA (1978) 84:1929-1933
- the lithium acetate method J. Bacteriol. (1983) 153:163-168) or the like may be enumerated.
- an expression vector such as pSG5, pREP4 or pZeoSV may be used.
- electroporation, the calcium phosphate precipitation method, or the like may be enumerated.
- plasmid DNA When a plasmid DNA is used as a vector DNA, if an EcoRI DNA fragment is to be inserted thereinto for example, the plasmid DNA is predigested with the restriction enzyme EcoRI before the insertion. Then, the DNA fragment and the digested vector DNA are mixed. The resultant mixture is treated with, for example, T4 DNA ligase (Takara Shuzo) to obtain a recombinant vector.
- T4 DNA ligase Takara Shuzo
- the prenyltransferase of the invention can be produced by culturing a transformant carrying the recombinant vector obtained above.
- the culture method may be the conventional solid culture, but preferably the liquid culture is employed.
- a medium for culturing the transformant a medium containing at least one nitrogen source selected from yeast extract, Peptone and meat extract; at least one inorganic salt such as dipotassium hydrogenphosphate, magnesium sulfate or ferric chloride; and, if necessary, sugar materials, antibiotics and vitamins may be used, for example.
- IPTG or the like may be added to the medium to induce the expression of the gene.
- the pH of the medium at the start of culture is adjusted to 6.8-7.5.
- the culture is conducted usually at 28-42° C., preferably at around 37° C., for 5 hours to overnight. Aeration agitation culture, shaking culture, or the like may be employed.
- the prenyltransferase of the invention may be recovered by conventional protein purification techniques.
- cells are crushed by lysis treatment with an enzyme such as lysozyme, sonication, grinding treatment or the like to release the prenyltransferase outside the cells. Then, insoluble materials are removed by filtration, centrifugation or the like to thereby obtain a crude polypeptide solution.
- an enzyme such as lysozyme, sonication, grinding treatment or the like to release the prenyltransferase outside the cells.
- insoluble materials are removed by filtration, centrifugation or the like to thereby obtain a crude polypeptide solution.
- Ubiquinones are known as a constituent of the electron transport system in a number of organisms. The length of their isoprenoid side chains varies with organism species. E. coli ubiquinone has an isoprenoid side chain of 8 isoprene units supplied by OPP synthetase; the ubiquinone of budding yeast Saccharomyces cerevisiae has a side chain of 6 isoprene units; and human ubiquinone has a side chain of 10 isoprene units.
- E. coli ubiquinone does not have an isoprenoid side chain of 10 isoprene units.
- a ubiquinone with an isoprenoid side chain of 10 isoprene units can be obtained from a transformant E. coli into which the gene of the invention has been introduced.
- ubiquinone-10 can be obtained.
- prenyltransferases have 7 regions which have been highly preserved beyond species. Then, the present inventor designed degenerate oligonucleotides based on those highly preserved amino acid sequences among various transferases. Using these oligonucleotides as primers in various combinations, PCR was performed with genomic DNA from P. denitrificans as a template. Using the amplified partial sequence as a probe, screening was conducted to clone a prenyltransferase gene.
- restriction enzymes and other DNA modification enzymes used in the cloning were obtained from Takara Shuzo, Toyobo and New England BioLabs.
- P. denitrificans was inoculated into 100 ml of 802 medium (10 g of Polypeptone, 2 g of yeast extract, 1 g of MgSO 4 .7H 2 O, 1 liter of distilled water, pH 7.0) and cultured at 30° C. until saturation. Then, cells were harvested, and genomic DNA was prepared according to the method of Saito et al. (Biochim. Biophys. Acta 72, 619-629 (1963))
- P. denitrificans was obtained from American Type Culture Collection (ATCC14907).
- genomic DNA from P. denitrificans was partially digested with a restriction enzyme. DNA fragments of a specific length were recovered. Then, a library was prepared. By these procedures, screening efficiency is improved compared to the screening of an entire genomic library.
- the following 12 degenerate primers were designed based on highly preserved amino acid sequences among various prenyltransferases, particularly on those sequences which are peculiar to medium- or long-chain prenyltransferases such as hexaprenyl diphosphate (HexPP, C30) synthetase, heptaprenyl diphosphate (HepPP, C35) (Koike, T. et al. (1995) J. Biol. Chem. 270:18396-18400) synthetase and octaprenyl diphosphate (OctPP, C40) (Jeorg, J. et al., (1996) Proc. Natl. Acad. Sci. USA 91:2216-2220) synthetase.
- HexPP hexaprenyl diphosphate
- HepPP heptaprenyl diphosphate
- OctPP octaprenyl diphosphate
- S5 (designed based on SEQ ID NO: 6):
- A1 (designed based on SEQ ID NO: 13):
- A2 (designed based on SEQ ID NO: 8):
- A3 (designed based on SEQ ID NO: 9):
- A4 (designed based on SEQ ID NO: 10):
- A5 (designed based on SEQ ID NO: 11):
- A6 (designed based on SEQ ID NO: 12):
- a PCR was conducted using TaKaRa Taq from Takara Shuzo.
- the composition of the reaction mixture was as follows.
- the genomic DNA from P. denitrificans was used.
- TaKaRa Taq 2.5 U Tris-HCl (pH 8.3) 10 mM KCl 50 mM MgCl 2 1.5 mM dNTP mixture 0.2 mM each Template 0.1 ⁇ g Primer 1 (any one of SEQ ID NOS: 14-19) 2.5 ⁇ g Primer 2 (any one of SEQ ID NOS: 20-25) 2.5 ⁇ g H 2 O to make 100 ⁇ l
- the PCR was conducted with DNA Thermal Cycler PJ2000 (Takara Shuzo). The PCR cycles were as described below.
- amino acid sequence encoded by pCR14 exhibited 45.7% homology to the amino acid sequence of E. coli OctPP synthetase, 35.5% homology to the amino acid sequence of B. stearothermophilus HepPP synthetase, and 31.8% homology to the amino acid sequence of E. coli FPP synthetase (FIG. 5).
- PCR primers (BS and BA; FIG. 6) were newly designed based on its sequence located inside of the above-described degenerate oligo primers (S4 and A6). Using these primers, a DNA fragment to be used as a probe for hybridization was amplified by PCR and recovered.
- the amplification was conducted 30 cycles, 1 cycle consisting of denaturation at 97° C. for 30 seconds, annealing at 55° C. for 30 seconds and extension at 72° C. for 1 minute.
- a filter was prepared by the following procedures. The chromosomal DNA from P. denitrificans (10 ⁇ g) was completely digested with ApaI, EcoRI and BamHI separately. Each of these digests was electrophoresed on 0.5 ⁇ TBE/0.7% agarose gel, alkali denatured, and then transferred to a nitrocellulose membrane filter (Zeta Probe Blotting Membrane from BioRad or Hybond-N+ from Amersham).
- composition of a hybridization solution was varied as shown below depending on homology to the probe.
- the filter was incubated in the solution at a constant temperature of 42° C. to perform prehybridization and hybridization.
- the filter was exposed to a Fuji imaging plate and analyzed with Fuji BAS-2000 Bioimage Analyzer System.
- PCR was performed with these clones and pCR14 as templates. It was observed whether a band similar to that amplified in pCR14 is also amplified in these clones (FIG. 9).
- the PCR was performed 25 cycles, 1 cycle consisting of denaturation at 98° C. for 30 seconds, annealing at 67° C. for 30 seconds and extension at 74° C. for 30 seconds.
- p11A1 (lane 1) exhibited amplification of a DNA fragment of about 300 bp similar to the fragment amplified in pCR14 (lane 4) (FIG. 9). No amplification was recognized in p11A2 and p11C1 under these conditions. Therefore, it is believed that they do not contain a full length gene of interest or they contain a different prenyltransferase gene.
- the insert of p11A1 was expected to contain a full length of a prenyltransferase gene.
- the present inventor decided to determine the total base sequence for the prenyltransferase gene contained in p11A1. Deletion of p11A1 was allowed to proceed from the BglII site located 4 kbp downstream of the sequence identical with pCR14, and finally, DNA fragments were cut out at the BamHI site located 430 bp upstream of pCR14. The resultant fragments were ligated to pUC119 vector digested with SmaI and BamHI.
- the vectors were screened by colony hybridization.
- the recovered clone was cut with BglII and then digested from the 3′ end with exonuclease III. The reaction was terminated after an appropriate time period. Thereafter, resultant DNA fragments were blunt-ended with mung bean nuclease or Klenow fragment. Finally, the DNA fragments were cut out by digesting with BamHI.
- This ORF has 4 ATG codons which may be the translation initiation point. Of these, the third methionine which is close to Shine-Dalgarno consensus sequence and has a reasonable distance from it is believed to be the translation initiation point.
- this ORF has 34.9% homology to E. coli FPP synthetase; 31.1% homology to B. stearothermophilus FPP synthetase; 31.8% homology to E. uredovora GGPP synthetase; 26.3% homology to M. luteus BP-26 HexPP synthetase; 34.4% homology to B. stearothermophilus HepPP synthetase; and 44.2% homology to E. coli OctPP synthetase (FIG. 12).
- an upstream base sequence of about 1 kbp adjacent to the BamHI site upstream of the ORF was determined.
- an operon of 3.3 kpb exists in the upstream of the prenyltransferase gene, which operon is composed of the ⁇ -ketothiolase gene and acetyl-CoA reductase gene of P. denitrificans already cloned and analyzed (Yabutani, T. et al., (1995) FEMS Microbial. Lett. 133:85-90).
- these two genes are forming an operon, the operon is terminated by a terminator. Thus, they are not forming an operon with the gene of the invention (FIG. 13).
- a system which allows compulsive expression of the prenyltransferase with a strong trc promoter and SD sequence from pTrc99A was constructed by introducing an NcoI site into the initiation codon (ATG) of the ORF and then sub-cloning it into the NcoI site of a high expression vector pTrc99A.
- An expression plasmid was prepared by introducing into a plasmid an ORF which starts from an ATG methionine codon located at around the predicted position for the initiation codon based on the 7 preserved regions of known prenyltransferases.
- restriction sites were introduced into the ORF by PCR using variant oligoprimers so that the ORF could be introduced into the vector.
- An NcoI site CCATGG was introduced into the Met codon (ATG) which is the translation initiation point.
- GGATCC was introduced into 84 bp downstream of the termination codon TGA.
- primers were designed in such a manner that the amino acid immediately after the initiation codon was not changed. The sequences of the PCR primers for introducing restriction sites are as follows.
- the PCR was conducted 25 cycles, 1 cycle consisting of denaturation at 98° C. for 30 seconds, annealing at 67° C. for 30 seconds and extension at 74° C. for 30 seconds.
- E. coli DH5 ⁇ was transformed with this expression plasmid pDPm3.
- E. coli carrying the expression plasmid pDPm3 has been deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3 Higashi 1-chome, Tsukuba City, Ibaragi Pref., Japan) under Accession No. FERM P-16318.
- the E. coli transformed with the expression plasmid pDPm3 was inoculated into LB medium (1% bacto-tryptone, 0.5% yeast extract, 0.5% NaCl, 0.1% glucose) containing 50 ⁇ g/ml ampicillin and cultured overnight at 37° C. Subsequently, 1 ml of this culture fluid was inoculated into 100 ml of M9 nutrient medium (0.2% M9 salt, 0.2% glycerol, 0.2% yeast extract) containing 50 ⁇ g/ml ampicillin and cultured at 30° C.
- M9 nutrient medium 0.2% M9 salt, 0.2% glycerol, 0.2% yeast extract
- IPTG isopropyl ⁇ -D-thiogalactopyranoside
- the culture fluid was centrifuged at 4° C. at 1,000 ⁇ g for 10 minutes and washed with 50 mM potassium phosphate buffer (pH 7.2).
- the resultant cells were suspended in a lysis buffer (50 mM potassium phosphate buffer (pH 7.2), 5 mM EDTA, 1 mM ⁇ -mercaptoethanol, 1 mM PMSF) and subjected to sonication [(ultrasound 10 sec.+ice cooling 2 min.) ⁇ 10 cycles], to thereby disrupt cells.
- the sonication was conducted with Sonifier 250 from Branson. After disruption, the cell suspension was centrifuged at 4° C. at 15,000 ⁇ g for 30 minutes, and the supernatant was collected as a crude enzyme extract.
- a 200 ⁇ l reaction solution shown below was prepared using an appropriate amount of the crude enzyme extract, various allylic primers and [ 1-14 C]IPP (54 or 57 Ci/mol; Amersham). Potassium phosphate buffer (pH 7.2) 50 mM MgCl 2 5 mM ⁇ -mercaptoethanol 10 mM Triton X-100 0.5% [ 14 C] IPP (1Ci/mol) 125 ⁇ M Allylic primer 25 ⁇ M Crude Enzyme Extract Appropriate volume Total 200 ⁇ l
- the solution was incubated at 37° C. for 1 hour to allow an enzyme reaction. Then, 200 ⁇ l of saturated aqueous NaCl solution and 1 ml of n-BuOH saturated with saturated aqueous NaCl solution were added thereto and agitated well. The resultant solution was centrifuged to extract the reaction products. 200 ⁇ l of the BuOH layer was collected, and 3 ml of Clear Sol was added thereto. Then, the enzyme activity was determined by measuring the radioactivity in the BuOH extract with a liquid scintillation counter. The enzyme activity was expressed in unit, one unit being the amount of IPP (nmol) taken into the reaction products per 1 minute.
- the prenyl diphosphate generated by the prenyltransferase was hydrolyzed with an acid phosphatase.
- the resultant hydrolysate was analyzed by reversed phase thin layer liquid chromatography (TLC).
- the acid phosphatase was purchased from Boehringer Mannheim.
- As a thin layer chromatography plate LKC18 of Whatman Chemical Separation was used.
- reaction was performed using the crude enzyme extract.
- the reaction products (prenyl diphosphates) were extracted with n-butanol (n-BuOH) and hydrolyzed with an acid phosphatase into corresponding prenols in the reaction solution the composition of which is shown below (Fujii, H. et al. (1982) Biochem. Biophys. Acta. 712:716-718).
- Butanol layer 0.8 ml 1 M acetate buffer (pH 4.7) 0.57 ml Methanol 1.2 ml Acid phosphatase 2 mg H 2 O 0.43 ml Total 3 ml
- E. coli is known to have three prenyltransferase activities of FPP synthetase, OPP synthetase and undecaprenyl diphosphate synthetase.
- FPP synthetase OPP synthetase
- undecaprenyl diphosphate synthetase OPP synthetase
- FIG. 14 production of decaprenyl diphosphate has been confirmed (FIG. 14). Therefore, it has become clear that the gene of the invention is a DPP synthetase gene.
- this DPP synthetase exhibited the maximum activity with FPP (see Table 3; enzyme activity 54.4), though slight activity was observed with GPP.
- EEE-geranylgeranyl diphosphate (trans-GGPP) or ZEE-geranylgeranyl diphosphate (cis-GGPP) was used as a substrate, strong activity was observed with trans-GGPP while little activity was observed with cis-GGPP.
- Ubiquinones were extracted from the E. coli transformed with pDPm3, followed by analysis of the chain length of isoprene side chains. Ubiquinone extraction was performed as described below.
- the isolated gene is coding for a decaprenyl diphosphate synthetase.
- E. coli does not naturally have the ability to produce ubiquinone-10, it has become possible to allow E. coli to produce ubiquinone-10 by transforming this bacterium with this gene of the invention (FIG. 17).
- a decaprenyl diphosphate synthetase a gene coding for the synthetase, a recombinant vector comprising the gene, a transformant transformed with the vector, a method for producing a decaprenyl diphosphate synthetase, and a method for producing ubiquinone-10 with a transformed microorganism are provided.
- the enzyme and the gene of the present invention are useful for the production of the enzyme, the production of ubiquinone-10, and the like.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- 1. Field of the Invention
- The present invention relates to a decaprenyl diphosphate synthetase, a gene coding for the synthetase, a recombinant vector comprising the gene, a transformant transformed with the vector, a method for producing a decaprenyl diphosphate synthetase, and a method for producing ubiquinone-10.
- 2. Description of the Prior Art
- Isoprenoids are the most varied group of compounds including more than 23,000 species occurring in nature. They include sterols, carotenoids, sugar carrier lipids, prenyl quinones, prenylated proteins, etc. (FIG. 1). Those enzymes which catalyze the formation of carbon skeletons that will be the basis for the biosynthesis of these isoprenoid compounds (i.e., enzymes which catalyze the head-to-tail type condensation polymerization of isopentenyl diphosphate (IPP) that is 5-carbon isoprene unit) are generically called as prenyl diphosphate synthetase. Prenyl diphosphate synthetase is classified into 4 groups depeding on the chain length, conformation, etc. of the prenyl diphosphate generated (Table 1).
TABLE 1 Classification of Prenyltransferase Major Group Structure Characteristic Products Short-chain prenyl Homodimer Soluble C15, C20 diphosphate synthetase Medium-chain prenyl Heterodimer Soluble C30, C35 diphosphate synthetase (E)-polyprenyl Homodimer Activated by C40, C45, C50 diphosphate synthetase carrier proteins. (E)-polyprenyl Homodimer Activated by C45, C55 diphosphate synthetase lipids. - Short-chain prenyl diphosphate synthetase (prenyltransferase I) includes geranyl diphosphate (GPP, C10) synthetase, farnesyl diphosphate (FPP, C15) synthetase (Eberhardt, N. L. et al., (1975) J. Biol. Chem. 250:863-866), geranylgeranyl diphosphate (GGPP, C20) synthetase (Sagami, H. et al. (1994) J. Biol. Chem. 269: 20561-20566) and the like. The short-chain prenyl diphosphates biosynthesized by these enzymes are water-soluble. They may be supplied as an allyl primer substrate for polyprenyl diphosphate synthetase belonging to other groups.
- Medium-chain prenyl diphosphate synthetase (prenyltransferase II) includes hexaprenyl diphosphate (HexPP, C30) synthetase (Fujii, H. et al., (1982) J. Biol. Chem., 257:14610), heptaprenyl diphosphate (HepPP, C35) synthetase (Takahashi, I. et al., (1980) J. Biol Chem., 255: 4539) and the like. These enzymes are greatly different from the short-chain prenyl diphosphate synthetase described above in that they are heterodimeric enzymes composed of two proteins each of which does not have a catalytic function alone. Usually, these two proteins are dissociated, but when a substrate is present, they associate with each other to manifest a function as an enzyme. Although those products produced by such enzymes are highly hydrophobic and apt to form micelles, they do not require lipids nor surfactants for the manifestation of their enzyme activity. This is considered due to the fact that the medium-chain prenyl diphosphate synthetase is a special system in which such dynamic dissociation and association are repeated.
- E-type long-chain prenyl diphosphate synthetase (prenyltransferase III) includes octaprenyl diphosphate (OctPP, C40) synthetase, decaprenyl diphosphate (DPP, C50) synthetase and the like. Unlike prenyltransferase II, these enzymes are undissociable homodimers and activated by polyprenyl diphosphate carrier proteins (Ohnuma, S. et al., (1991) J. Biol. Chem. 266: 23706-23713). This activation is believed to maintain the catalyst turnover by removing hydrophobic reaction products from the active sites of these enzymes.
- Z-type long-chain prenyl diphosphate synthetase (prenyltransferase IV) includes nonaprenyl diphosphate (E,E-farnesyl-all-Z-hexaprenyl diphosphate, C45) synthetase, undecaprenyl diphosphate (E,E-farnesyl-all-Z-octaprenyl diphosphate, C55) synthetase and the like. Reaction products generated by these enzymes work as sugar carrier lipids in the biosynthesis of bacterial cell walls. These enzymes need the addition of a phospholipid or surfactant for the manifestation of their activity. DPP synthetase, which is classified into prenyltransferase III, is also known to require a surfactant for the manifestation of its enzyme activity.
- A soil bacteriumParacoccus denitrificans is a bacterium which is believed to be the origin of human mitochondria. The respiratory chain and the oxidative phosphorylation mechanism of this bacterium are more efficient and more united as one organization than those of other bacteria. Thus, the characteristics of P. denitrificans are more closer to those of mitochondria (John, P. et al., (1975) Nature, 254, 495-498). Three types of prenyl diphosphate synthetase activities have been confirmed from P. denitrificans (FIG. 2). They are activities of (i) FPP synthetase which catalyzes E-type condensation of dimethylallyl diphosphate (DMAPP) with 2 molecules of IPP to produce FPP; (ii) nonaprenyl diphosphate (NPP) synthetase which catalyzes Z-type condensation of FPP with 6 molecules of IPP to produce NPP (Ishii, K. et al., (1986) Biochem. J., 233, 773-777); and (iii) DPP synthetase which catalyzes E-type condensation of FPP with 7 molecules of IPP to produce DPP (Ishii K. et al., (1983) Biochem. Biophys. Res. Commun., 116, 500-506).
- NPP produced by NPP synthetase becomes a sugar carrier lipid which is essential for the biosynthesis of the cell wall of this bacterium. However, unlike several E-type prenyl diphosphate synthetases which have been already cloned and analyzed, prenyl diphosphate synthetases such as NPP synthetase and undecaprenyl diphosphate synthetase which catalyze Z-type condensation reaction have not been elucidated yet in relationships between their structures and enzymatic functions.
- DPP produced by DPP synthetase is metabolized on the prenyl side chain of ubiquinone-10 (a constituent of the electron transport system) produced by this bacterium. All of the C30-C50 polyprenyl diphosphates biosynthesized by bacterial prenyltransferase II or III are provided as a side chain precursor of the corresponding menaquinone or ubiquinone. Therefore, the chain length of the product of each enzyme is directly reflected in the side chain length of the prenylquinone of the bacterium from which the enzyme is derived. Among prenylquinones, ubiquinone-10 is industrially extracted fromParacoccus denitrificans and used as pharmaceuticals since it has the same side chain length as that of human coenzyme Q (CoQ). Ubiquinone has been known to be effective for chronic heart diseases (Yamamura, T. (1977) Clinical Status of Coenzyme Q and Prospects 281-298). Ubiquinone-10 is also effective as an antiarrhythmic agent and, thus, is utilized for the prevention of arrhythmia and the like (Fujioka, T. et al. (1983) Tohoku J. Exp. Med. 141, 453-463).
- It is the object of the present invention to provide a decaprenyl diphosphate synthetase, a gene coding for the synthetase, a recombinant vector comprising the gene, a transformant transformed with the vector, a method for producing the decaprenyl diphosphate synthetase, and a method for producing ubiquinone-10.
- As a result of intensive and extensive researches toward the solution of the above assignment, the present inventor has succeeded in cloning a gene coding for a long-chain decaprenyl diphosphate synthetase fromParacoccus denitrificans. Thus, the present invention has been achieved.
- The present invention relates to a recombinant protein (a) or (b) described below:
- (a) a protein having the amino acid sequence shown in SEQ ID NO: 2
- (b) a protein which has the amino acid sequence shown in SEQ ID NO:2 having deletion, substitution or addition of at least one amino acid and which has decaprenyl diphosphate synthetase activity.
- The present invention also relates to a gene coding for the recombinant protein (a) or (b) described above. Specific examples of this gene include a gene comprising the base sequence shown in SEQ ID NO: 1.
- Further, the present invention relates to a recombinant vector comprising the above gene.
- The present invention further relates to a transformant transformed with the above vector.
- The present invention further relates to a method for producing a decaprenyl diphosphate synthetase comprising culturing the above transformant in a medium and recovering a decaprenyl diphosphate synthetase from the resultant culture.
- The present invention further relates to a method for producing ubiquinone-10 comprising extracting ubiquinone-10 from the above transformant.
- FIG. 1 is a diagram showing the biosynthesis of isoprenoid compounds.
- FIG. 2 is a diagram showing the biosynthetic pathway of prenyl diphosphates inP. denitrificans.
- FIG. 3 is a diagram showing the design of PCR primers.
- FIG. 4 is a photograph showing the results of PCR.
- FIG. 5 is a diagram showing comparison of amino acid homology.
- FIG. 6 is a diagram showing the design of PCR primers.
- FIG. 7 provides two electrophorograms showing the results of Southern hybridization.
- FIG. 8 is an electrophorogram showing the results of Southern hybridization.
- FIG. 9 is an electrophorogram showing the results of Southern hybridization.
- FIG. 10 is a diagram showing the structure of plasmid p11A1.
- FIG. 11 is a diagram showing the open reading frame contained in plasmid p11A1.
- FIG. 12 is a diagram showing comparison of amino acid sequences for various prenyltransferases.
- FIG. 13 is an illustrative diagram showing genes located upstream and downstream of the gene of the present invention.
- FIG. 14 provides photographs of reversed phase thin layer liquid chromatograms.
- FIG. 15 is a photograph showing the results of SDS-polyacrylamide gel electrophoresis.
- FIG. 16 provides HPLC charts showing the results of analysis of quinone side chains.
- FIG. 17 is a graph showing the ratios of ubiquinone production in individual microorganisms.
- Hereinbelow, the present invention will be described in detail.
- It is known that prenyl diphosphate synthetases (hereinafter, sometimes referred to as “prenyltransferase(s)”) have 7 regions which have been preserved highly beyond species (Koyama, T. et al., (1993) J. Biochem. 113:355). In the present invention, degenerate oligonucleotides for use as primers are designed based on the amino acid sequences highly preserved among various prenyltransferases. Using these primers in various combinations, PCR is performed with genomic DNA from the soil bacteriumParacoccus denitrificans (hereinafter referred to as “=P. denitrificans”) as a template. The gene of the present invention can be obtained by screening the genomic DNA using one of the amplified partial sequences as a probe.
- 1. Cloning of a Gene Coding for a Prenyl Diphosphate Synthetase
- (1) Preparation of Genomic DNA
- First, genomic DNA is prepared from cultures cells of a prenyl diphosphate synthetase producing bacterium such as the soil bacteriumP. denitrificans.
- The preparation of genomic DNA may be performed by any of the conventional methods. For example, genomic DNA can be prepared easily by the following procedures. The above bacterium is inoculated into a medium containing 2 g of yeast extract, 10 g of Polypeptone, 1 g of MgSO4.7H2O and 1 liter of distilled water (802 medium) and cultured at 30° C. for one to several days (until saturation); subsequently, bacterial cells are treated with lysozyme and further treated with a surfactant such as sodium lauryl sulfate; thereafter, proteins are removed therefrom with an organic solvent such as phenol, chloroform or ether; then, genomic DNA is precipitated with ethanol.
- Subsequently, a genomic DNA library is prepared by ligating the resultant genomic DNA to a vector plasmid. This preparation may be performed by conventional methods. For example, genomic DNA strand and plasmid DNA strand are cut with an appropriate restriction enzyme (e.g., EcoRI, BamHI, Hind III, Sau3AI, MboI, PstI); then, these strands are just treated with a DNA ligase (e.g., T4 DNA ligase), or they are treated with a DNA ligase after treatment with a terminal transferase or DNA polymerase depending on the states of the resultant fragment ends, to thereby ligate DNA strands (Molecular Cloning, Cold Spring Harbor Laboratory, 269, 1982; Methods in Enzymol., 68, 41, 1979). As a vector useful for this purpose, λ phage vectors (e.g., λgt10, Charon 4A, EMBL-3), plasmid vectors (e.g., pBR322, pSC101, pUC19, pUC119, pACYC117) or like may be enumerated. After incorporation of the above DNA fragment into such a vector,Escherichia coli (e.g., DH1, HB101, JM109, C600, MV1184, TH2) is transformed with the vector to obtain a genomic DNA library.
- (2) Preparation of Probes for Screening
- First, probes to be used for screening the above genomic DNA library by hybridization are prepared. For the preparation of probes which are highly specific to a DNA of interest, it is considered appropriate to prepare oligonucleotides coding for the regions with highly preserved amino acid residues among various organism species. These probes can be obtained by conventional chemical synthesis. As amino acid sequences which satisfy the above conditions, the following preserved amino acid sequences are selected based on FIG. 3.
- The sequence “(Gly or Glu) Gly Lys Arg Ile Arg Pro” (SEQ ID NO: 1) in Region I
- The sequences “(Thr or Met) Ala (Ser or Thr) Leu (Val, Ile or Leu) His Asp” (SEQ ID NO: 4), “Ala Ser Leu Leu His Asp Asp” (SEQ ID NO: 5) and “Ala Asp Leu Arg Arg Gly” (SEQ ID NO: 6) in Region II
- The sequence “Leu Ala Gly Asp Phe Leu Leu” (SEQ ID NO: 7) in Region III
- The sequence “Gly Glu Leu Gln Leu” (SEQ ID NO: 8) in Region IV
- The sequence “Lys Thr Ala Leu Leu Ile” (SEQ ID NO: 9) in Region V
- The sequences “Phe Gln Leu Ile Asp Asp” (SEQ ID NO: 10), “Asp Asp Ile Leu Asp Phe” (SEQ ID NO: 11), “Gly Lys Asn Val Gly Asp Asp” (SEQ ID NO: 12) and “Asp Asp (Leu, Ile or Met) Leu Asp (Tyr or Phe) (Asn or Thr)” (SEQ ID NO: 13) in Region VI.
- Regions I, II, III, IV, V and VI correspond to amino acid positions from 43 to 53, from 74 to 95, from 110 to 119, from 145 to 150, from 170 to 175 and from 204 to 230, respectively, of the amino acid sequence for aBacillus stearothermophylus-derived heptaprenyl diphosphate synthetase disclosed in Koike T. et al., (1995) J. Biol. Chem. 270:18398-18400.
- Examination of preserved amino acid sequences in various organism species can be performed among known prenyl diphosphate synthetases, such as FPS synthetases fromBacillus stearothermophylus, Escherichia coli, Saccharomyces cerevisiae, rat and human; GGPS synthetases from Erwinia herbicola and Erwinia uredovora; and HexPS synthetase from Saccharomyces cerevisiae.
- Based on the amino acid sequences thus selected, the oligonucleotide probes shown below are prepared.
- Briefly, in the present invention, the following 12 degenerate primers are designed based on highly preserved amino acid sequences among various prenyltransferases and on those sequences which are peculiar to medium- or long-chain prenyltransferases such as hexaprenyl diphosphate (HexPP, C30) synthetase, heptaprenyl diphosphate (Hepp, C35) (Koike, T. et al. (1995) J. Biol. Chem. 270:18396-18400) synthetase and octaprenyl diphosphate (OctPP, C40) (Jeorg, J. et al., (1996) Proc. Natl. Acad. Sci. USA 91:2216-2220) synthetase.
- Sense Primers:
- S1 (designed based on SEQ ID NO: 3):
- 5′-(CG)(AG)CGG(AT)AA(AG)C(AG)(CGT)AT(CGT)CGTCC-3′ (SEQ ID NO: 14)
- S2 (designed based on SEQ ID NO: 4):
- 5′-A(CT)(ACGT)GC(GT)(AT)C(ACGT)CT(ACGT)(CGT)T(ACGT)CACGA-3′ (SEQ ID NO: 15)
- S3 (designed based on SEQ ID NO: 3):
- 5′-GG(ACGT)GG(ACGT)AA(AG)CG(ACGT)AT(ACT)CG(ACGT)CC-3′ (SEQ ID NO: 16)
- S4 (designed based on SEQ ID NO: 5):
- 5′-GC(ACGT)TC(ACGT)CT(ACGT)CT(ACGT)CA(CT)GACGA-3′ (SEQ ID NO: 17)
- S5 (designed based on SEQ ID NO: 6):
- 5′-GC(ACGT)GA(CT)TT(AG)(AC)G(ACGT)(AC)G(ACGT)GG-3′ (SEQ ID NO: 18)
- S6 (designed based on SEQ ID NO: 7):
- 5′-(CT)T(ACGT)GC(ACGT)GG(ACGT)GA(CT)TT(CT)TT(AG)TT-3′ (SEQ ID NO: 19)
- Antisense Primers:
- A1 (designed based on SEQ ID NO: 13):
- 5′-(GT)T(AG)(AT)AATCGAG(TA)A(ACT)(AG)TC(AG)TC-3′ (SEQ ID NO: 20)
- A2 (designed based on SEQ ID NO: 8):
- 5′-(ACGT)A(AG)(CT)TG(CT)AA(ACGT)A(AG)(CT)TC(ACGT)CC-3′ (SEQ ID NO: 21)
- A3 (designed based on SEQ ID NO: 9):
- 5′-(AGT)AT(ACGT)AG(ACGT)AG(ACGT)GC(ACGT)GT(TC)TT-3′ (SEQ ID NO: 22)
- A4 (designed based on SEQ ID NO: 10):
- 5′-(AG)TC(AG)TC(AGT)AT(CT)AA(CT)TG(AG)AA-3′ (SEQ ID NO: 23)
- A5 (designed based on SEQ ID NO: 11):
- 5′-(AG)AA(AG)TC(ACGT)A(AG)(AGT)AT(AG)TC(AG)TC-3′ (SEQ ID NO: 24)
- A6 (designed based on SEQ ID NO: 12):
- 5′-(AG)TC(AG)TC(ACGT)CC(ACGT)AC(AG)TT(CT)TT(ACGT)CC-3′ (SEQ ID NO: 25)
- (3) Cloning of a Part of a Prenyl Diphosphate Synthetase Gene
- The screening ofP. denitrificans genomic DNA for the gene of the present invention can be performed by conventional methods such as Southern hybridization, colony hybridization, PCR or a combination of these methods.
- For example, genomic DNA fromP. denitrificans is subjected to PCR using a combination of the primers described above to thereby amplify a DNA fragment containing a part of a prenyl diphosphate synthetase gene. The fragment which is believed to contain a part of the target gene is separated by electrophoresis and recovered. After ligation of the DNA fragment to a vector, E. coli is transformed with the vector, and the DNA fragment is cloned. The thus obtained DNA fragment (pCR14) is suitable as a probe for obtaining a full length prenyl diphosphate synthetase gene.
- (4) Cloning of a Full Length Prenyl Diphosphate Synthetase Gene
- As described above, probe pCR14 is a DNA fragment containing a part of the prenyl diphosphate synthetase gene ofP. denitrificans. Thus, the screening for a gene encoding the peptide of the prenyl diphosphate synthetase of the invention is performed, for example, as described below using pCR14.
- The genomic DNA partially digested with Sau3AI is electrophoresed. Resultant DNA fragments of 5-10 kbp are extracted from the agarose gel and inserted into the BamHI site of pUC119. With this plasmid,E. coli JM109 is transformed to prepare a DNA library. Then, colony hybridization is performed with pCR14 as a probe.
- (5) Determination of the Base Sequence
- Each of the clones thus obtained is digested with an appropriate restriction enzyme, followed by agarose gel electrophoresis. From the migration pattern and distance, a restriction map is prepared. Based on this map, deletion of the DNA fragment (i.e., to make the DNA fragment shorter) is carried out to thereby obtain a minimum clone exhibiting activity. Then, the base sequence for the activity-exhibiting DNA is analyzed.
- The base sequence may be determined using two plasmids which contain the same insert DNA truncated at one end in opposite directions.
- The screened clone is digested with an appropriate restriction enzyme (such as EcoRI, PstI) and cloned into a plasmid (such as pUC119, pUC19). Then, the base sequence for the DNA of interest can be determined by conventional base sequence analysis methods, for example, the dideoxy method by Sangar et al. (Proc. Natl. Acad. Sci. USA (1977) 74:5463). The determination of the base sequence may be performed with an automatic base sequence analyzer such as T7 Sequencing Kit (Pharmacia).
- (6) Identification of the Gene
- A region which is expected to be a prenyl diphosphate synthetase gene is integrated into an expression vector, with whichE. coli is transformed. The transformant is cultured and resultant cells are crushed to obtain a crude enzyme extract. By determining the activity of this extract, the prenyl diphosphate synthetase, particularly, decaprenyl diphosphate synthetase of the invention can be identified. Also, by determining the length of the ubiquinone side chain of the transformant, the gene can be identified.
- The base sequence for the gene coding for the prenyltransferase of the invention is shown in SEQ ID NO: 1. The amino acid sequence for the prenyltransferase of the invention is shown in SEQ ID NO: 2. However, the amino acid sequence of SEQ ID NO: 2 may have a mutation such as deletion, substitution or addition of at least one amino acid (preferably, one or several amino acids) as long as it can exhibit prenyltransferase activity. In addition to the base sequence shown in SEQ ID NO: 1, a base sequence which codes for the same polypeptide and which is only different from SEQ ID NO: 1 in a degenerate codon(s) is also included in the gene of the present invention.
- Introduction of the above mutation can be performed easily by conventional methods such as the method of Kunkel (Proc. Natl. Acad. Sci. (1985) 82:488).
- Once the base sequence has been thus determined, the target gene can be obtained by hybridization with a DNA fragment prepared by chemical synthesis or PCR.
- 2. Preparation of a Recombinant Vector and a Transformant
- A recombinant vector of the invention can be obtained by integrating the gene of the invention into an appropriate vector. A transformant of the invention can be obtained by introducing the recombinant vector into a host which is compatible with the initial vector.
- A purified gene is inserted into a restriction site or multi-cloning site of a suitable vector DNA to obtain a recombinant vector. With this vector, a host is transformed.
- A vector DNA into which a DNA fragment is inserted is not particularly limited as long as it is replicable in a host cell. For example, a plasmid DNA or phage DNA may be used. As a plasmid DNA, plasmid pUC118 (Takara Shuzo), plasmid pUC119 (Takara Shuzo), pBluescript SK+ (Stratagene), pGEM-T (Promega) or the like may be enumerated. As a phage DNA, M13mp18, M13mp19 or the like may be enumerated.
- As a host, any host may be used as long as it can express the gene of interest. Either an eukaryotic or prokaryotic cell may be used. For example, bacteria such asEscherichia coli, Bacillus subtilis; yeast such as Saccharomyces cerevisiae; and animal cells such as COS cells, CHO cells, etc. may be enumerated.
- When a bacterium such asE. coli is used as a host, preferably the recombinant vector of the invention is capable of autonomous replication in the host and yet has a constitution comprising a promoter, the gene of the invention and a transcription terminator sequence. Specific examples of such E. coli include XL1-Blue (Stratagene) and JM109 (Takara Shuzo). Specific examples of an expression vector include pTrc99A and pET expression systems. As a promoter, any promoter may be used as long as it can express the gene of interest in the host such as E. coli. Specific examples of the promoter include E. coli- or phage-derived promoters such as trp promoter, lac promoter, PL promoter and PR promoter. In the present invention, the transformation of E. coli can be performed, for example, by the method of Hanahan (J. Mol. Biol. (1983) 166:557).
- When yeast is used as a host, an expression vector such as YEp13 or YCp50 may be used. As a promoter,
gal 1 promoter orgal 10 promoter may be used, for example. As a method for introducing a recombinant vector into yeast, electroporation (Methods. Enzymol. (1990) 194:182-187), the spheroplast method (Proc. Natl. Acad. Sci. USA (1978) 84:1929-1933), the lithium acetate method (J. Bacteriol. (1983) 153:163-168) or the like may be enumerated. - When an animal cell is used as a host, an expression vector such as pSG5, pREP4 or pZeoSV may be used. As a method for introducing a recombinant DNA into an animal cell, electroporation, the calcium phosphate precipitation method, or the like may be enumerated.
- When a plasmid DNA is used as a vector DNA, if an EcoRI DNA fragment is to be inserted thereinto for example, the plasmid DNA is predigested with the restriction enzyme EcoRI before the insertion. Then, the DNA fragment and the digested vector DNA are mixed. The resultant mixture is treated with, for example, T4 DNA ligase (Takara Shuzo) to obtain a recombinant vector.
- 3. Production of the Prenyltransferase
- The prenyltransferase of the invention can be produced by culturing a transformant carrying the recombinant vector obtained above. The culture method may be the conventional solid culture, but preferably the liquid culture is employed.
- As a medium for culturing the transformant, a medium containing at least one nitrogen source selected from yeast extract, Peptone and meat extract; at least one inorganic salt such as dipotassium hydrogenphosphate, magnesium sulfate or ferric chloride; and, if necessary, sugar materials, antibiotics and vitamins may be used, for example. If necessary, IPTG or the like may be added to the medium to induce the expression of the gene. The pH of the medium at the start of culture is adjusted to 6.8-7.5. The culture is conducted usually at 28-42° C., preferably at around 37° C., for 5 hours to overnight. Aeration agitation culture, shaking culture, or the like may be employed.
- After completion of the culture, the prenyltransferase of the invention may be recovered by conventional protein purification techniques.
- Briefly, cells are crushed by lysis treatment with an enzyme such as lysozyme, sonication, grinding treatment or the like to release the prenyltransferase outside the cells. Then, insoluble materials are removed by filtration, centrifugation or the like to thereby obtain a crude polypeptide solution.
- For further purification of the peptide from the above crude polypeptide solution, conventional protein purification methods may be used. For example, ammonium sulfate fractionation, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, affinity chromatography and electrophoresis may be used independently or in combination.
- 4. Production of Ubiquinone-10
- Ubiquinones are known as a constituent of the electron transport system in a number of organisms. The length of their isoprenoid side chains varies with organism species.E. coli ubiquinone has an isoprenoid side chain of 8 isoprene units supplied by OPP synthetase; the ubiquinone of budding yeast Saccharomyces cerevisiae has a side chain of 6 isoprene units; and human ubiquinone has a side chain of 10 isoprene units.
- Generally,E. coli ubiquinone does not have an isoprenoid side chain of 10 isoprene units. However, a ubiquinone with an isoprenoid side chain of 10 isoprene units (ubiquinone-10) can be obtained from a transformant E. coli into which the gene of the invention has been introduced. By crushing the transformant E. coli by sonication or the like, extracting the cell components with hexane and finally applying them to HPLC, ubiquinone-10 can be obtained.
- Hereinbelow, the present invention will be described in more detail with reference to the following Examples, which should not be construed as limiting the technical scope of the invention.
- It is known that prenyltransferases have 7 regions which have been highly preserved beyond species. Then, the present inventor designed degenerate oligonucleotides based on those highly preserved amino acid sequences among various transferases. Using these oligonucleotides as primers in various combinations, PCR was performed with genomic DNA fromP. denitrificans as a template. Using the amplified partial sequence as a probe, screening was conducted to clone a prenyltransferase gene.
- The restriction enzymes and other DNA modification enzymes used in the cloning were obtained from Takara Shuzo, Toyobo and New England BioLabs.
- (1) Preparation of Genomic DNA fromP. denitrificans and Creation of a Genomic Library
-
-
- The genomic DNA fromP. denitrificans was partially digested with a restriction enzyme. DNA fragments of a specific length were recovered. Then, a library was prepared. By these procedures, screening efficiency is improved compared to the screening of an entire genomic library.
- Briefly, 1 U of Sau3A1 was added to 50 μg of the genomic DNA. The resultant mixture was incubated at 37° C. A specific amount of sample was taken in every 5 minutes from the start of the incubation up to 90 minutes. Then, the reaction was terminated. Each sample was electrophoresed on 0.8% agarose gel. Fragments of 5-10 kbp were recovered from the gel and ligated to pUC119-BamHI vector individually. With this vector,E. coli DH5α was transformed. The resultant transformants were cultured in LB medium to prepare glycerol stocks having a glycerol concentration of 30%. Thus, 10 libraries each containing about 2000 clones were prepared. From these libraries, plasmid DNAs were recovered.
- (2) Design of PCR Primers
- In the present invention, the following 12 degenerate primers were designed based on highly preserved amino acid sequences among various prenyltransferases, particularly on those sequences which are peculiar to medium- or long-chain prenyltransferases such as hexaprenyl diphosphate (HexPP, C30) synthetase, heptaprenyl diphosphate (HepPP, C35) (Koike, T. et al. (1995) J. Biol. Chem. 270:18396-18400) synthetase and octaprenyl diphosphate (OctPP, C40) (Jeorg, J. et al., (1996) Proc. Natl. Acad. Sci. USA 91:2216-2220) synthetase.
- Sense Primers:
- S1 (designed based on SEQ ID NO: 3):
- 5′-(CG)(AG)CGG(AT)AA(AG)C(AG)(CGT)AT(CGT)CGTCC-3′ (SEQ ID NO: 14)
- S2 (designed based on SEQ ID NO: 4):
- 5′-A(CT)(ACGT)GC(GT)(AT)C(ACGT)CT(ACGT)(CGT)T(ACGT)CACGA-3′ (SEQ ID NO: 15)
- S3 (designed based on SEQ ID NO: 3):
- 5′-GG(ACGT)GG(ACGT)AA(AG)CG(ACGT)AT(ACT)CG(ACGT)CC-3′ (SEQ ID NO: 16)
- S4 (designed based on SEQ ID NO: 5):
- 5′-GC(ACGT)TC(ACGT)CT(ACGT)CT(ACGT)CA(CT)GACGA-3′ (SEQ ID NO: 17)
- S5 (designed based on SEQ ID NO: 6):
- 5′-GC(ACGT)GA(CT)TT(AG)(AC)G(ACGT)(AC)G(ACGT)GG-3′ (SEQ ID NO: 18)
- S6 (designed based on SEQ ID NO: 7):
- 5′-(CT)T(ACGT)GC(ACGT)GG(ACGT)GA(CT)TT(CT)TT(AG)TT-3′ (SEQ ID NO: 19)
- Antisense Primers:
- A1 (designed based on SEQ ID NO: 13):
- 5′-(GT)T(AG)(AT)AATCGAG(TA)A(ACT)(AG)TC(AG)TC-3′ (SEQ ID NO: 20)
- A2 (designed based on SEQ ID NO: 8):
- 5′-(ACGT)A(AG)(CT)TG(CT)AA(ACGT)A(AG)(CT)TC(ACGT)CC-3′ (SEQ ID NO: 21)
- A3 (designed based on SEQ ID NO: 9):
- 5′-(AGT)AT(ACGT)AG(ACGT)AG(ACGT)GC(ACGT)GT(TC)TT-3′ (SEQ ID NO: 22)
- A4 (designed based on SEQ ID NO: 10):
- 5′-(AG)TC(AG)TC(AGT)AT(CT)AA(CT)TG(AG)AA-3′ (SEQ ID NO: 23)
- A5 (designed based on SEQ ID NO: 11):
- 5′-(AG)AA(AG)TC(ACGT)A(AG)(AGT)AT(AG)TC(AG)TC-3′ (SEQ ID NO: 24)
- A6 (designed based on SEQ ID NO: 12):
- 5′-(AG)TC(AG)TC(ACGT)CC(ACGT)AC(AG)TT(CT)TT(ACGT)CC-3′ (SEQ ID NO: 25)
- (3) Amplification of a Prenyltransferase Gene Fragment by PCR
- A PCR was conducted using TaKaRa Taq from Takara Shuzo. Usually, the composition of the reaction mixture was as follows. As a template, the genomic DNA fromP. denitrificans was used.
TaKaRa Taq 2.5 U Tris-HCl (pH 8.3) 10 mM KCl 50 mM MgCl2 1.5 mM dNTP mixture 0.2 mM each Template 0.1 μg Primer 1 (any one of SEQ ID NOS: 14-19) 2.5 μg Primer 2 (any one of SEQ ID NOS: 20-25) 2.5 μg H2O to make 100 μl - The PCR was conducted with DNA Thermal Cycler PJ2000 (Takara Shuzo). The PCR cycles were as described below.
- Briefly, 5 cycles of denaturation at 97° C. for 30 seconds, annealing at 40° C. for 30 seconds, and extension at 70° C. for 1 minute; then 30 cycles of denaturation at 97° C. for 30 seconds, annealing at 55° C. for 30 seconds, and extension at 70° C. for 1 minute were carried out.
- After completion of the PCR, the products were subjected to electrophoresis with 1×TBE/5% acrylamide gel. The amplified DNA fragments were confirmed (FIG. 4) and recovered by the gel recovery method. The DNA clone obtained by the reaction using primers S4 (SEQ ID NO: 17) and A6 (SEQ ID NO:25) was designated “pCR14”. Then, pCR14 was purified and sub-cloned into pT7BlueT-vector (Novagen). The base sequence of pCR14 was determined with an automatic base sequence analyzer (ABIPRISM™ 310 Genetic Analyzer), followed by analysis using a gene analysis software GENETIX for comparison with the amino acid sequences of other prenyltransferases.
- As a result, the amino acid sequence encoded by pCR14 exhibited 45.7% homology to the amino acid sequence ofE. coli OctPP synthetase, 35.5% homology to the amino acid sequence of B. stearothermophilus HepPP synthetase, and 31.8% homology to the amino acid sequence of E. coli FPP synthetase (FIG. 5).
- (4) Southern Blot Analysis
- For the sub-cloned and sequenced PCR product (i.e., pCR14), PCR primers (BS and BA; FIG. 6) were newly designed based on its sequence located inside of the above-described degenerate oligo primers (S4 and A6). Using these primers, a DNA fragment to be used as a probe for hybridization was amplified by PCR and recovered.
- Sense Primer
- BS: 5′-CCGGCCGACGCAAACCTT-3′ (SEQ ID NO: 26)
- Antisense Primer
- BA: 5′-CTGCTGCACCGCCGGGTC-3′ (SEQ ID NO: 27)
- The amplification was conducted 30 cycles, 1 cycle consisting of denaturation at 97° C. for 30 seconds, annealing at 55° C. for 30 seconds and extension at 72° C. for 1 minute.
- Using a 300 bp fragment thus amplified as a probe, Southern blot analysis of the genomic DNA fromP. denitrificans was performed. The PCR product was labelled with a [α-35S] dCTP (Amersham) using a commercial kit (Ready To Go DNA Labelling Beads; Pharmacia). The labelling was performed according to the protocol attached to the kit.
- A filter was prepared by the following procedures. The chromosomal DNA fromP. denitrificans (10 μg) was completely digested with ApaI, EcoRI and BamHI separately. Each of these digests was electrophoresed on 0.5×TBE/0.7% agarose gel, alkali denatured, and then transferred to a nitrocellulose membrane filter (Zeta Probe Blotting Membrane from BioRad or Hybond-N+ from Amersham).
- The composition of a hybridization solution was varied as shown below depending on homology to the probe. The filter was incubated in the solution at a constant temperature of 42° C. to perform prehybridization and hybridization.
(i) Stringent conditions (homology = approx. 100%) 5 × SSC 5 × Denhardt's solution 1% SDS 0.2 mg/ml denatured salmon sperm DNA 50% formamide 35S-probe (this is omitted in the prehybridization) -
(ii) Moderate conditions (homology = approx. 50%) 5 × SSC 5 × Denhardt's solution 1% SDS 0.2 mg/ml denatured salmon sperm DNA 25% formamide 35S-probe (this is omitted in the prehybridization) - Conditions for washing after the hybridization were also varied as follows.
- Stringent conditions (homology=approx. 100%):
- 0.1% SDS, 0.1×SSC, at 68° C.
- Moderate conditions (homology=approx. 50%):
- 0.1% SDS, 2×SSC, at 55° C.
- After washing, the filter was exposed to a Fuji imaging plate and analyzed with Fuji BAS-2000 Bioimage Analyzer System.
- As a result, under the stringent conditions (under which the homology between the detected bands and the primers would be approximately 100%), a 16.5 kbp band was detected when the genomic DNA had been digested with ApaI; a 18.5 kbp band was detected when the genomic DNA had been digested with EcoRI; a 11.2 kbp band and a slightly weakly hybridizing 4.2 kbp band were detected when the genomic DNA had been digested with BamHI (FIG. 7A). The slightly weak 4.2 kbp band is predicted to contain a sequence which is highly homologous to the sequences obtained this time that appear to code for a prenyltransferase gene. In other words, this 4.2 kbp band is predicted to contain another prenyltransferase gene (FPP synthetase) ofP. denitrificans.
- On the other hand, under moderate conditions (under which the homology between the detected bands and the primers would be approximately 50%), additional bands were confirmed as follows: a 7.4 kbp band when the genomic DNA had been digested with ApaI, a 5.3 kbp band when the genomic DNA had been digested with EcoRI and a 5.2 kbp band when the genomic DNA had been digested with BamHI (FIG. 7B). These bands are very likely to contain other prenyltransferase genes.
- (5) Recovery of a Full Length Gene by Colony Hybridization
- In order to recover a full length gene containing the gene fragment amplified by PCR, colony hybridization was conducted using the same probe as used in the Southern hybridization. First, the genomic DNA fromP. denitrificans was partially digested with Sau3AI. Then, 5-10 kbp fragments were recovered and sub-cloned into pUC119-BamHI vector to thereby obtain 10 libraries separately each of which contained about 2000 clones. Plasmid was recovered from each library, digested with EcoRI and then subjected to Southern hybridization. Thus, those libraries which surely contained the gene of interest were selected.
- As a result, strongly hybridizing bands were detected in libraries Nos. 9 and 10 among the 10 libraries (Nos. 1-10) (FIG. 8).
- Then, library No. 10 which had exhibited the strongest bands in Southern hybridization was subjected to colony hybridization to thereby obtain 3 positive clones. Plasmids were recovered from them and designated p11A1, p11A2 and p11C1, respectively. Since each of these clones had an insert of about 7 kbp, it was confirmed by PCR if these clones contained the gene of interest.
- Briefly, using PCR primers BS and BA described above, a PCR was performed with these clones and pCR14 as templates. It was observed whether a band similar to that amplified in pCR14 is also amplified in these clones (FIG. 9). The PCR was performed 25 cycles, 1 cycle consisting of denaturation at 98° C. for 30 seconds, annealing at 67° C. for 30 seconds and extension at 74° C. for 30 seconds.
- As a result, only p11A1 (lane 1) exhibited amplification of a DNA fragment of about 300 bp similar to the fragment amplified in pCR14 (lane 4) (FIG. 9). No amplification was recognized in p11A2 and p11C1 under these conditions. Therefore, it is believed that they do not contain a full length gene of interest or they contain a different prenyltransferase gene.
- Subsequently, by preparing a restriction map for p11A1, it was ascertained where the sequence identical with pCR14 is contained in its insert of about 7 kbp (FIG. 10). Also, it was confirmed that a full length prenyltransferase gene was contained (FIG. 10). As a result, it was found that the sequence identical with pCR14 is located about 1.1-1.5 kbp from an end of the insert of p11A1. Considering that the average gene length of prenyltransferases is about 1 kbp and that the preserved Regions II to VI are contained in pCR14, the insert of p11A1 was expected to contain a full length of a prenyltransferase gene.
- (6) Deletion of p11A1 and Determination of the Base Sequence
- First, the present inventor decided to determine the total base sequence for the prenyltransferase gene contained in p11A1. Deletion of p11A1 was allowed to proceed from the BglII site located 4 kbp downstream of the sequence identical with pCR14, and finally, DNA fragments were cut out at the BamHI site located 430 bp upstream of pCR14. The resultant fragments were ligated to pUC119 vector digested with SmaI and BamHI.
- The vectors were screened by colony hybridization. The recovered clone was cut with BglII and then digested from the 3′ end with exonuclease III. The reaction was terminated after an appropriate time period. Thereafter, resultant DNA fragments were blunt-ended with mung bean nuclease or Klenow fragment. Finally, the DNA fragments were cut out by digesting with BamHI.
- These fragments were electrophoresed on 3.5% acrylamide gel. Thereafter, the fragments were recovered from the gel and used to transformE. coli DH5α. Several single transformants were selected and plasmids were recovered therefrom.
- These plasmids carrying a deletion product were applied to a sequencer (from ABI) to thereby determine the base sequence for the full length gene.
- As a result, an ORF was found out which contains a base sequence identical with pCR14 and has in its amino acid primary sequence the 7 preserved areas peculiar to prenyltransferases (FIG. 11; SEQ ID NO: 28).
- This ORF has 4 ATG codons which may be the translation initiation point. Of these, the third methionine which is close to Shine-Dalgarno consensus sequence and has a reasonable distance from it is believed to be the translation initiation point.
- The amino acid primary sequence of this ORF was compared with the primary sequences of major prenyltransferases so far cloned. As a result, this ORF has 34.9% homology toE. coli FPP synthetase; 31.1% homology to B. stearothermophilus FPP synthetase; 31.8% homology to E. uredovora GGPP synthetase; 26.3% homology to M. luteus BP-26 HexPP synthetase; 34.4% homology to B. stearothermophilus HepPP synthetase; and 44.2% homology to E. coli OctPP synthetase (FIG. 12).
- During the process of deletion, a downstream base sequence of about 1 kbp adjacent to the ORF of the prenyltransferase contained in p11A1 was determined.
- As a result, a typical terminator sequence characterized by a repetitive sequence and repetition of T was found at 25 bp downstream of the ORF termination codon TGA (nucleotide positions from 1174 to 1201 in FIG. 11 and SEQ ID NO: 28). Therefore, it was found that there is no ORF forming an operon in the downstream of this prenyltransferase gene.
- Also, an upstream base sequence of about 1 kbp adjacent to the BamHI site upstream of the ORF was determined. As a result, it was found that an operon of 3.3 kpb exists in the upstream of the prenyltransferase gene, which operon is composed of the β-ketothiolase gene and acetyl-CoA reductase gene ofP. denitrificans already cloned and analyzed (Yabutani, T. et al., (1995) FEMS Microbial. Lett. 133:85-90). Although these two genes are forming an operon, the operon is terminated by a terminator. Thus, they are not forming an operon with the gene of the invention (FIG. 13).
- In the present invention, a system which allows compulsive expression of the prenyltransferase with a strong trc promoter and SD sequence from pTrc99A was constructed by introducing an NcoI site into the initiation codon (ATG) of the ORF and then sub-cloning it into the NcoI site of a high expression vector pTrc99A.
- An expression plasmid was prepared by introducing into a plasmid an ORF which starts from an ATG methionine codon located at around the predicted position for the initiation codon based on the 7 preserved regions of known prenyltransferases.
- (1) Preparation of a High Expression Plasmid
- Of those ORFs which were believed to be a prenyltransferase as a result of the confirmation of base sequences, the ORF in which the third methionine is the initiation codon was introduced into the NcoI-BamHI site of the expression vector pTrc99A.
- First, restriction sites were introduced into the ORF by PCR using variant oligoprimers so that the ORF could be introduced into the vector. An NcoI site (CCATGG) was introduced into the Met codon (ATG) which is the translation initiation point. Also, a BamHI site (GGATCC) was introduced into 84 bp downstream of the termination codon TGA. In the introduction, primers were designed in such a manner that the amino acid immediately after the initiation codon was not changed. The sequences of the PCR primers for introducing restriction sites are as follows.
- Sense Primer
- DP03: 5′-ATCG+E,uns CCCATGGGCATGAACGAAAACGTCTC-3′ (SEQ ID NO: 29) NcoI
- Antisense Primer
- DP13 : 5′-GAG+E,uns GGATCCTATAACAACTGAGGCAGCG-3′ (SEQ ID NO: 30) BamHI
- By performing a PCR with these primers, a gene fragment having a restriction site at each end was amplified. As a polymerase for use in the PCR, KOD DNA polymerase from Toyobo was employed which is reported to be superior to Taq DNA polymerase and Pfu DNA polymerase in accuracy in DNA synthesis and amplification efficiency (Bernes, W. M. (1994) Proc. Natl. Acad. Sci. USA 91:2216-2220). The composition of the reaction mixture and the PCR cycles are as described below.
KOD DNA polymerase 2.5 U Tris-HCl (pH 8.3) 120 mM KCl 10 mM (NH4)2SO4 6 mM MgCl 2 1 mM dNTP mixture 0.2 mM each Template 0.1 μg Primer (DPO3) 1.25 μM Primer (DP13) 1.25 μM H2O to make 50 μl - The PCR was conducted 25 cycles, 1 cycle consisting of denaturation at 98° C. for 30 seconds, annealing at 67° C. for 30 seconds and extension at 74° C. for 30 seconds.
- After completion of the PCR, the products were digested with NcoI and BamHI, electrophoresed on 0.8% agarose gel and recovered. The resultant NcoI-BamHI gene fragment was sub-cloned into the NcoI-BamHI site of pTrc99A (Amann, E. et al. (1988) Gene 69:301-305). The thus obtained expression plasmid was designated pDPm3. This plasmid was also sequenced to confirm the sequence of the vector and the junction sites.
- As a result, it was confirmed that the ORF of the prenyltransferase is surely inserted into this plasmid and ligated without frameshift to the NcoI site.
- Thereafter,E. coli DH5α was transformed with this expression plasmid pDPm3.
- TheE. coli carrying the expression plasmid pDPm3 (pDPm3/DH5α) has been deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3 Higashi 1-chome, Tsukuba City, Ibaragi Pref., Japan) under Accession No. FERM P-16318.
- (2) High Expression of the Prenyltransferase inE. coli
- TheE. coli transformed with the expression plasmid pDPm3 was inoculated into LB medium (1% bacto-tryptone, 0.5% yeast extract, 0.5% NaCl, 0.1% glucose) containing 50 μg/ml ampicillin and cultured overnight at 37° C. Subsequently, 1 ml of this culture fluid was inoculated into 100 ml of M9 nutrient medium (0.2% M9 salt, 0.2% glycerol, 0.2% yeast extract) containing 50 μg/ml ampicillin and cultured at 30° C. When the turbidity reached at A600=0.6-0.8, isopropyl β-D-thiogalactopyranoside (IPTG) was added thereto to give a final concentration of 1 mM. Then, the cells were cultured overnight at 30° C.
- The culture fluid was centrifuged at 4° C. at 1,000×g for 10 minutes and washed with 50 mM potassium phosphate buffer (pH 7.2). The resultant cells were suspended in a lysis buffer (50 mM potassium phosphate buffer (pH 7.2), 5 mM EDTA, 1 mM β-mercaptoethanol, 1 mM PMSF) and subjected to sonication [(
ultrasound 10 sec.+ice cooling 2 min.)×10 cycles], to thereby disrupt cells. The sonication was conducted with Sonifier 250 from Branson. After disruption, the cell suspension was centrifuged at 4° C. at 15,000×g for 30 minutes, and the supernatant was collected as a crude enzyme extract. - Subsequently, prenyltransferase activity was determined as described below.
- A 200 μl reaction solution shown below was prepared using an appropriate amount of the crude enzyme extract, various allylic primers and [1-14C]IPP (54 or 57 Ci/mol; Amersham).
Potassium phosphate buffer (pH 7.2) 50 mM MgCl 2 5 mM β- mercaptoethanol 10 mM Triton X-100 0.5% [14C] IPP (1Ci/mol) 125 μM Allylic primer 25 μM Crude Enzyme Extract Appropriate volume Total 200 μl - The solution was incubated at 37° C. for 1 hour to allow an enzyme reaction. Then, 200 μl of saturated aqueous NaCl solution and 1 ml of n-BuOH saturated with saturated aqueous NaCl solution were added thereto and agitated well. The resultant solution was centrifuged to extract the reaction products. 200 μl of the BuOH layer was collected, and 3 ml of Clear Sol was added thereto. Then, the enzyme activity was determined by measuring the radioactivity in the BuOH extract with a liquid scintillation counter. The enzyme activity was expressed in unit, one unit being the amount of IPP (nmol) taken into the reaction products per 1 minute.
- As a result, prenyltransferase activity which is believed to be derived from a foreign gene was confirmed in the IPTG-induced, pDPm3-transformedE. coli (Table 2).
TABLE 2 Enzyme Activity (×10−3 unit) Transformant −Triton X-100 +Triton X-100 DH5α/pDPm3 1.27 0.553 DH5α/pDPm3 + IPTG 9.05 54.4 DH5α/pUC119 + IPTG 1.78 1.78 - It is noted that significant transferase activity was not confirmed inE. coli which was transformed with pDPm3 but not induced with IPTG. This indicates that the expression of this prenyltransferase activity is under the strong control of the trc promoter.
- (3) Analysis of the Reaction Product by Reversed Phase TLC
- Subsequently, the prenyl diphosphate generated by the prenyltransferase was hydrolyzed with an acid phosphatase. The resultant hydrolysate was analyzed by reversed phase thin layer liquid chromatography (TLC). The acid phosphatase was purchased from Boehringer Mannheim. As a thin layer chromatography plate, LKC18 of Whatman Chemical Separation was used.
- Briefly, a reaction was performed using the crude enzyme extract. The reaction products (prenyl diphosphates) were extracted with n-butanol (n-BuOH) and hydrolyzed with an acid phosphatase into corresponding prenols in the reaction solution the composition of which is shown below (Fujii, H. et al. (1982) Biochem. Biophys. Acta. 712:716-718).
Butanol layer 0.8 ml 1 M acetate buffer (pH 4.7) 0.57 ml Methanol 1.2 ml Acid phosphatase 2 mg H2O 0.43 ml Total 3 ml - The hydrolysis was performed overnight at 37° C. After completion of the reaction, 1 ml of saturated aqueous NaCl solution and 3 ml of n-pentane were added thereto and agitated, to thereby extract the prenol with the pentane. The pentane layer was recovered and washed with H2O. Then, the pentane extract was concentrated with a centrifugal evaporator and developed by reversed phase TLC (with LKC-18) to identify the reaction products (eluent: aceton:H2O=19:1). The positions of various prenols used as standard samples were visualized by exposure to iodine vapor. The TLC plate was exposed to a Fuji imaging plate, which was then analyzed with Fuji BAS-2000 Bioimage Analyzer to detect the positions of radioactive prenols.
- The results are shown in FIG. 14.
-
- The substrate specificity of this DPP synthetase has been examined on various allyl primers. The unit of enzyme activity is as defined above.
- As a result, this DPP synthetase exhibited the maximum activity with FPP (see Table 3; enzyme activity 54.4), though slight activity was observed with GPP. When EEE-geranylgeranyl diphosphate (trans-GGPP) or ZEE-geranylgeranyl diphosphate (cis-GGPP) was used as a substrate, strong activity was observed with trans-GGPP while little activity was observed with cis-GGPP. These results support that the enzyme of the invention is an enzyme catalyzing E-type chain elongation.
TABLE 3 Substrate Specificity of the Prenyltransferase Enzyme Activity (×10−3 unit) Allylic Substrate −Triton X-100 +Triton X-100 DMAPP 1.63 4.17 GPP 1.78 19.8 EE-FPP 9.05 54.4 EEE-GGPP 3.22 35.33 ZEE-GGPP 2.47 3.68 - (4) Confirmation of High Expression of the Prenyltransferase
- High expression of the prenyltransferase by means of the expression plasmid was confirmed as described below. Briefly, the crude enzyme extract was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using RESEP GEL 12.5% (Wakamori K. K.). The positions of bands stained with Coomassie Brilliant Blue R-250 were compared with molecular markers (SDS-PAGE Molecular Weight Standards, Broad Range; BioRad).
- The procedures basically followed the method of Laemmli (Laemmli U.K. (1970) Nature 227:680-685).
- As a result, a band which is believed to be due to high expression was observed at around 36 kDa in the precipitated fraction after centrifugation at 15,000×g (FIG. 15, lane 6).
- (5) Analysis of the Ubiquinone Side Chain Length
- Ubiquinones were extracted from theE. coli transformed with pDPm3, followed by analysis of the chain length of isoprene side chains. Ubiquinone extraction was performed as described below.
- First, 0.3 g of wet cells were suspended in 2 ml of methanol-0.3% NaCl solution (10:1, v/v) (hereinafter referred to as “extraction solution”) and sonicated (30 min×4 times). Then, 1 ml of extraction solution was added thereto, and hexane extraction was performed twice. The extract was washed with extraction solution to remove the hexane and then dissolved in 1 ml ethanol, followed by HPLC.
- HPLC equipment from Hitachi was used. As a column, LiChrosorb RP-18 (5 μm) (Merck) was used. As an eluent, EtOH (99.8%) was fed at 1 ml/min. Detection was conducted at 275 nm.
- The results are shown in FIG. 16 and Table 4. In theE. coli transformed with the vector plasmid pTrc99A alone, only ubiquinone-8 (UQ-8) was detected. On the other hand, in the E. coli transformed with pDPm3, about 20% of the total ubiquinone was replaced with ubiquinone-10. Further, in the E. coli transformed with pDPm3 and cultured under induction with IPTG, about 70% of the total ubiquinone was replaced with UQ-10.
TABLE 4 Ubiquinone Yield (μg/g wet cell) Cell UQ-8 UQ-10 DH5 α/pUC119 72.7 — DH5 α/pDPm3 16.2 4.51 DH5 α/pDPm3 + IPTG 6.05 17.5 P. denitrificans — 256 - From the above, it has been confirmed that the isolated gene is coding for a decaprenyl diphosphate synthetase. AlthoughE. coli does not naturally have the ability to produce ubiquinone-10, it has become possible to allow E. coli to produce ubiquinone-10 by transforming this bacterium with this gene of the invention (FIG. 17).
- According to the present invention, a decaprenyl diphosphate synthetase, a gene coding for the synthetase, a recombinant vector comprising the gene, a transformant transformed with the vector, a method for producing a decaprenyl diphosphate synthetase, and a method for producing ubiquinone-10 with a transformed microorganism are provided. The enzyme and the gene of the present invention are useful for the production of the enzyme, the production of ubiquinone-10, and the like.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/803,951 US6413761B2 (en) | 1997-09-17 | 2001-03-13 | Decaprenyl diphosphate synthetase gene |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25167597 | 1997-09-17 | ||
JP9-251675 | 1997-09-17 | ||
JP251675/19997 | 1997-09-17 | ||
US09/025,819 US6225097B1 (en) | 1997-09-17 | 1998-02-19 | Decaprenyl diphosphate synthetase gene |
US09/803,951 US6413761B2 (en) | 1997-09-17 | 2001-03-13 | Decaprenyl diphosphate synthetase gene |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/025,819 Division US6225097B1 (en) | 1997-09-17 | 1998-02-19 | Decaprenyl diphosphate synthetase gene |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010019838A1 true US20010019838A1 (en) | 2001-09-06 |
US6413761B2 US6413761B2 (en) | 2002-07-02 |
Family
ID=17226352
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/025,819 Expired - Fee Related US6225097B1 (en) | 1997-09-17 | 1998-02-19 | Decaprenyl diphosphate synthetase gene |
US09/803,951 Expired - Fee Related US6413761B2 (en) | 1997-09-17 | 2001-03-13 | Decaprenyl diphosphate synthetase gene |
US09/808,126 Expired - Fee Related US6410280B1 (en) | 1997-09-17 | 2001-03-15 | Decaprenyl diphosphate synthetase gene |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/025,819 Expired - Fee Related US6225097B1 (en) | 1997-09-17 | 1998-02-19 | Decaprenyl diphosphate synthetase gene |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,126 Expired - Fee Related US6410280B1 (en) | 1997-09-17 | 2001-03-15 | Decaprenyl diphosphate synthetase gene |
Country Status (1)
Country | Link |
---|---|
US (3) | US6225097B1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1227155B1 (en) | 1999-10-14 | 2008-04-09 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing ubiquinone-10 |
DE60132498T2 (en) * | 2000-09-29 | 2009-01-15 | Cargill, Inc., Wayzata | ISOPRENOIDPRODUKTION |
CZ20033381A3 (en) * | 2001-05-11 | 2004-04-14 | Kaneka Corporation | Expression process of prenyldiphosphatsynthase with a long chain |
US7723290B2 (en) | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
EP1898942B1 (en) * | 2004-07-14 | 2012-09-05 | Biospectrum, Inc. | Antiproliferative peptides |
CA2718469C (en) | 2008-03-17 | 2017-07-04 | National Research Council Of Canada | Aromatic prenyltransferase from hop |
JP6166858B2 (en) | 2011-03-02 | 2017-07-19 | バイオインセプト、エルエルシー | Compositions and methods for the treatment of intracellular damage |
EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | Compositions and methods for the treatment of neurodamage |
US11096987B2 (en) | 2015-08-28 | 2021-08-24 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
-
1998
- 1998-02-19 US US09/025,819 patent/US6225097B1/en not_active Expired - Fee Related
-
2001
- 2001-03-13 US US09/803,951 patent/US6413761B2/en not_active Expired - Fee Related
- 2001-03-15 US US09/808,126 patent/US6410280B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6410280B1 (en) | 2002-06-25 |
US6413761B2 (en) | 2002-07-02 |
US6225097B1 (en) | 2001-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4643569B2 (en) | Feedback resistant mevalonate kinase | |
Okada et al. | Molecular cloning and mutational analysis of the ddsA gene encoding decaprenyl diphosphate synthase from Gluconobacter suboxydans | |
EP0763542B1 (en) | Long-chain prenyl diphosphate synthase | |
US6410280B1 (en) | Decaprenyl diphosphate synthetase gene | |
US6395525B2 (en) | Geranyl diphosphate synthase genes | |
US6316216B1 (en) | Mutated prenyl diphosphate synthases | |
KR100252689B1 (en) | Mutant prenyl diphosphate synthase | |
US6174715B1 (en) | Prenyl diphosphate synthetase genes | |
KR100252529B1 (en) | Farnesyl diphosphate synthase | |
US8163525B2 (en) | Method of expressing long-chain prenyl diphosphate synthase | |
JPH11178590A (en) | Gene for enzyme for synthesizing decaprenyl diphosphate | |
JP3651473B2 (en) | Prenyl diphosphate synthase gene | |
US20040067566A1 (en) | Process for producing coenzyme q10 | |
JP3536594B2 (en) | Prenyl diphosphate synthase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TOYOTA JIDOSHA KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OBATA, SHUSEI;NISHINO, TOKUZO;KOYAMA, TANETOSHI;AND OTHERS;REEL/FRAME:011686/0249 Effective date: 19980212 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100702 |